Unlocking Value:
Algorithm-Based Diagnostics
for a Billion-Dollar Market
Cardiac amyloidosis was long misclassified as rare. New data proves otherwise — and SYGNAL is the missing link between available therapy and correct diagnosis.
A Massive, Untapped Market
Autopsy-based studies reveal: approximately 25% of patients over 80 have amyloid deposits in the heart. Even in routine cohorts — HFpEF patients (up to 13%) and pre-TAVI (up to 16%) — prevalence is alarmingly high. The problem? These patients go undiagnosed for years. Average diagnostic delay exceeds 6 years.
… of patients >80 years have cardiac amyloid deposits
… of HFpEF patients >60 years have ATTRwt amyloidosis
… of TAVI patients have concurrent ATTR amyloidosis
Therapy Meets a Diagnostic Vacuum
The pharmaceutical industry has launched a therapeutic revolution with TTR stabilizers (Tafamidis, Acoramidis) and RNA silencers (Vutrisiran). These drugs reduce mortality by over 30%. But the commercial and clinical success of these high-value therapies depends on one bottleneck: timely diagnosis.
Life-Saving Therapies
Tafamidis · Acoramidis · Vutrisiran · CRISPR pipeline
Timely Diagnosis
SYGNAL closes this gap
Patients in Therapy
Early, systematic, scalable
SYGNAL: The Game Changer
Proprietary Pattern Recognition
While human experts often fail at complex symptom overlaps, the SYGNAL algorithm detects subtle ECG signal patterns — QRS voltage discrepancies and specific biomarker constellations — that precede clinical diagnosis by years.
Non-Invasive Scalability
We replace the need for invasive myocardial biopsies and complex expert workups with a digital screening solution that integrates seamlessly into clinical workflows — deployable at any hospital with a standard ECG device.
Data Infrastructure
Our technology addresses the fragmentation of care — where patients get 'lost' between cardiologists, neurologists, and other specialists — by making systemic connections visible through data.
Patent-Protected IP
SYGNAL's core algorithm is patent-pending. Our proprietary technology transforms diagnosis from an accidental event into a systematic process — making the invisible visible, precisely, early, and cost-efficiently.
Why Now?
Exponential Market Dynamics
The amyloidosis therapy market is growing exponentially. With new approvals (Acoramidis March 2025, Vutrisiran June 2025) and CRISPR approaches in Phase III, demand for efficient patient identification is escalating dramatically.
Economic Relevance
Misdiagnosis costs the healthcare system billions through ineffective treatments and repeated hospitalizations. SYGNAL reduces this waste and routes patients to the correct value chain — creating value for pharma, payers, and providers alike.
First-Mover Advantage
SYGNAL is the world's first dedicated screening technology for cardiac amyloidosis via standard ECG. Anumana proved the concept, AccurKardia validated the IP space — MYCOR owns the European market.
An estimated 3 million patients worldwide — the majority go undetected.
Our vision: Reverse that ratio. Through systematic screening and identification of diagnostic red flags, we enable patients to be treated before irreversible damage occurs. SYGNAL — Making the invisible visible.
Multidisciplinary Founding Team
Developed by an interdisciplinary team of cardiologists, electrophysiologists, algorithm experts from leading university hospitals, and experienced entrepreneurs. SYGNAL by myCor combines clinical expertise, technological precision, and the execution power of an ambitious HealthTech startup.